



7/02/04

APW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Case No. 99,005-D1-CO )

Re Application of:

Irwin Braude

Serial No.: 10/784,413

Filed: February 23, 2004

For: Methods for Anti-Tumor Therapy

Art Unit: 1614

Examiner: To be Assigned

Commissioner for Patents and Trademarks  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

1. We are transmitting herewith the attached papers for the above identified patent application:

- ☒ Transmittal
- ☒ IDS and 1449 Forms in compliance with the continuing duty of candor as set forth in 37 C.F.R. § 1.56. ( 9 Sheets);
- ☒ Copy of International Search Report of Corresponding PCT Application No. PCT/US01/26972 (9 Sheets);
- ☒ Return Receipt Postcard

2. With respect to fees:

- ☒ No fee is required.

3. **GENERAL AUTHORIZATION TO CHARGE OR CREDIT FEES:** Please charge any additional fees or credit overpayment to Deposit Account No. **13-2490**. A duplicate copy of this sheet is enclosed.

4. **CERTIFICATE OF MAILING BY "EXPRESS MAIL" UNDER 37 CFR § 1.10:** The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as "Express Mail Post Office to Addressee" in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 30<sup>th</sup> day of June, 2004. Express Mail No. **EV334698315US**.

By:

David S. Harper  
Reg. No. 42,636

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

This Information Disclosure Statement is being filed:

- ☒ within three months of the filing date of a national application; within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or before the mailing date of a first Office Action on the merits. 37 C.F.R. § 1.97 (b)
- ☐ **after** three months of the filing date of a national application, or the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or **after** the mailing date of a first Office Action on the merits, but **before** the mailing date of a Final Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311 (whichever occurs first), and includes (37 C.F.R. § 1.97 (c):

☐ the Certification under 37 C.F.R. § 1.97(e) (see "Certification" below)

**OR**

- ☐ the fee of \$240 set forth in 37 C.F.R. § 1.17(p) (see "Fees" below).
- ☐ **after** a Final Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311 (whichever occurs first), but before, or simultaneously with, the payment of the issue fee, and includes the Certification under 37 C.F.R. § 1.97(e) (see "Certification" below), and the Petition Fee set forth in 37 C.F.R. § 1.17(i) (see "Fees" and "Method of Payment of Fees" below). Applicants hereby petitions for consideration of the Information Disclosure Statement submitted herewith and the accompanying references in examination of the subject patent application.

#### CERTIFICATION

- ☐ The **undersigned** hereby certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.
- ☐ The **undersigned** hereby certifies that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual

designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

FEES

- ☒ No fee is owed by the applicant(s).  
☐ The **IDS Fee of \$240.00** under 37 C.F.R. § 1.17(p) is enclosed herewith.  
☐ The **Petition Fee of \$130.00** set forth in 37 C.F.R. § 1.17(i) is enclosed herewith.

METHOD OF PAYMENT OF FEES

- ☐ Attached is a check in the amount of \$240.00.  
☐ Charge Deposit Account No. 13-2490 in the amount of \$ \_\_\_\_\_ . (A duplicate copy of this communication is enclosed for that purpose.)


Please charge any underpayment or credit any overpayment in connection with this communication to Deposit Account No. 13-2490. A duplicate copy of this communication is enclosed for this purpose.

**CERTIFICATE OF MAILING AS "EXPRESS MAIL" (37 CFR 1.10)** I hereby certify that this correspondence and all attached paper(s) or fee(s) is being deposited with sufficient postage, with the United States Postal Service as EXPRESS MAIL POST OFFICE TO ADDRESSEE in an envelope addressed to: The Honorable Commissioner for Patents and Trademarks, P.O. Box 1450, Alexandria, VA 22313, with sufficient postage, on this 30<sup>th</sup> Day of June, 2004. under Express Mail Certificate No. EV334698315US.

Date: \_\_\_\_\_

6/30/04


Respectfully submitted,



David S. Harper  
Registration No. 42,636

Telephone: 312-913-0001  
Facsimile: 312-913-0002

**McDonnell Boehnen Hulbert & Berghoff**  
300 South Wacker Drive  
Chicago, IL 60606



FORM PTO-1449 (Modified)		Attorney Docket No.: 99,005-D1CO		Application No.: 10/784,413		
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Braude				
		Filing Date: February 23, 2004		Group: 1614		
Reference Designation		U.S. PATENT DOCUMENTS				Page 1
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
____ AA	6,335,334	Jan. 1, 2002	Schindler et al.	514	231.5	Jul. 8, 1999
____ AB	US 2002/0061887 A1	Pub. Date May 23, 2002	Schindler et al.			Nov. 28, 2001
FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
____ AC	WO 00/02851		PCT			No
____ AD	WO 00/78145		PCT			No
____ AE	DE 3523705		Deutschland			No
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
____ AF						
____ AG						
____ AH						
EXAMINER		DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449  
(Rev. 2-32)U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docke

Serial No.

99,005-D1 89

10/784,413

SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant: Irwin Braude

Filing Date:

Group:

02/23/04

1614

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1.	6,458,845	10/1/02	Joseph Weinstock, et al.			June 21, 2000
	2.	6,469,043	10/22/02	Toru Haneda, et al.			February 24, 2000

## Foreign Documents

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	3.	WO 00/78145	12/28/00	Joseph Weinstock, et al.			June 21, 2000

## Other Documents

	4.	Bold, et al., (2000), J. Med. Chem., "New Anilinophthalazines as Potent and Orally Well Absorbed inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis", Vol: 43, pp. 2310-2323.
	5.	Dreys, et al., (2000), Cancer Research, "Effects of PTK787/ZK 222584, a Specific Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, on Primary Tumor, Metastasis, Vessel Density, and blood Flow in a Murine Renal Cell Carcinoma Model", Vol: 60, pp. 4819-4824.
	6.	Owa, et al., (1999), J. Med. Chem., "Discovery of Novel Antitumor Sulfofnamides Targeting G1 Phase of the Cell Cycle", Vol: 42, pp. 3789-3799.
	7.	Schlaeppli, et al., (1999), Cancer and Metastasis Reviews, "Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors", Vol: 18, pp. 473-481.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

8.	Supuran, et al., (2001), Bioorganic and Medicinal Chemistry, "Carbonic Anhydrase Inhibitors: Sulfonamides as Antitumor Agents", Vol: 9, pp. 703-714.
9.	Wood, et al., (2000), Cancer Research, "PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration", Vol: 60, pp. 2178-2189.
10.	Xu, et al., (2000), International Journal of Oncology, "Inhibition of Malignant Ascites and Growth of Human Ovarian Carcinoma by Oral Administration of a Potent Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases", Vol: 16, pp. 445-454.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

Serial No.

99,005-D1 co

10/784,413

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant: Irwin Braude

Filing Date:

Group:

02/23/04

1614



U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1.	5,919,682	7-6-99	Bettie Sue Masters, et al.			
	2.	5,658,565	8-19-97	Timothy R. Billiar, et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	3.	WO 00/02850	1-20-00	PCT				
	4.	WO 98/02170	1/22/98	PCT				
	5.	WO 96/04311	2/15/96	PCT				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	6.	Horowitz, et al., (1988), Journal of Clinical Oncology, Vol. 6 No. 2, pp. 308-314.
	7.	Bailar, et al., (1997), N. Engl. J. Med., Vol. 336, pp. 1569-1574.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Dock. No.  
99,005-D1 60Serial No.  
10/784,413SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant: Irwin Braude

Filing Date:  
02/23/04Group:  
1614

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Abstract Translation	
							Yes	No
1.		DE 198 30 431	1/13/00	German			X	
2.		DE 198 30 430	1/13/00	German			X	
3.		SU 1794941	2-15-93	Russian			X	
4.		SU 1796617	2-23-93	Russian			X	
5.		SU 1754712	8-15-92	Russian			X	
6.		SU 1685936	10-23-91	Russian			X	
7.		SU 1687586	10-30-91	Russian			X	
8.		EP A 216 028	4/1/87	Europe			X	
9.		3,523,705	1-8-97	German			X	
10.		EP A 420-805 A3	10-16-91	Europe			X	
11.		EP A 420-805 A2	10-16-91	Europe			X	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.